KTTA

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:KTTA

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/27	07:44	GlobeNewswire Inc.	Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/09/26	20:02	GlobeNewswire Inc.	Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/09/09	21:01	GlobeNewswire Inc.	Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/09/03	21:02	GlobeNewswire Inc.	Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/08/28	22:11	GlobeNewswire Inc.	Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/08/14	05:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/06/13	19:59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/05/28	19:59	GlobeNewswire Inc.	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/04/29	20:59	GlobeNewswire Inc.	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/04/24	20:59	GlobeNewswire Inc.	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/03/02	11:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/02/13	21:59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/19	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/08	21:59	GlobeNewswire Inc.	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/03	06:47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2024/01/02	22:35	GlobeNewswire Inc.	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/29	07:00	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/29	07:00	GlobeNewswire Inc.	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/29	01:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/20	07:26	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/20	07:21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/20	07:19	GlobeNewswire Inc.	Pasithea Therapeutics Announces Results from 2023 Annual Meeting	NASDAQ:KTTA	Pasithea Therapeutics Corporation
2023/12/11	22:01	GlobeNewswire Inc.	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	NASDAQ:KTTA	Pasithea Therapeutics Corporation